Researchers find new target for kidney cancer therapy

November 10, 2014

CINCINNATI--Cincinnati Cancer Center (CCC) researchers have discovered that a membrane channel, Transient Receptor Potential Melastatin 3, or TRPM3, promotes growth of kidney cancer tumors, and targeting this channel therapeutically could lead to more treatments for a disease that currently has few treatment options.

A membrane channel is a family of proteins that allows the movement of ions, water or other solutions to pass through the membrane.

These findings are being published in the Nov. 10, 2014, edition of the journal Cancer Cell.

"Metastatic clear cell kidney cancer is largely incurable, and existing treatments for the disease are only minimally effective," says Maria Czyzyk-Krzeska, MD, PhD, senior author of the study, member of the CCC and the University of Cincinnati (UC) Cancer Institute and professor in UC's department of cancer biology. "Our team found a new target in kidney cancer known as TRPM3. TRPM3 is increased in 60 percent of kidney clear cell carcinomas where it promotes growth of tumors by stimulating intracellular pathways that initiate autophagy--a quality control process in cancer cells that also generates intracellular nutrients.

"During tumor growth, cancer cells become addicted to autophagy as a source of nutrients. Furthermore, autophagy contributes to chemotherapy resistance in kidney cancer. The new target we've identified regulates kidney cancer cell autophagy."

The experiments were conducted using animal models, human cell cultures and tumor specimens. The researchers analyzed expression of the channel, its effect on tumor growth and on autophagy and how regulation of autophagy contributed to tumor growth.

"Our discovery of a TRPM3 stimulated network in the regulation of autophagy and kidney cancer growth could lead to use of the channel as a new actionable target in renal cancer. There are already FDA-approved TRPM3 inhibitors on the market, so this is quite promising," Czyzyk-Krezeska says.
-end-
Co-investigators on this research include cancer biology faculty members and former fellows including Daniel Hall, Nicholas Cost (who is currently assistant professor of urology at the University of Colorado Medical Center, Denver), Shailaja Hedge, Emily Kellner, Olga Mikhaylova, Yiwen Stratton, Birgit Ehmer, William Abplanalp, Raghav Pandey, and David Plas; Cincinnati Children's Hospital Medical Center bioinformatics faculty member Jacek Biesiada; Christian Harteneck from the University of Tübingen, Tübingen, Germany; and Jarek Meller from UC's departments of environmental health and bioinformatics.

This work was funded by the National Institutes of Health (CA122346, CA133164 and CA168815), a Veterans Affairs Merit Award and a UC Center for Environmental Genetics Award (P30-ES006096).

University of Cincinnati Academic Health Center

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.